CD44 and neoplasm: Recently, the combination of CD44-targeted NIR-PIT and programmed cell death protein 1 (PD-1) immune checkpoint blockade was reported to induce massive tumor cell death and innate priming of polyclonal, cancer antigen-specific T-cell responses in several cancer models, resulting in complete tumor rejection and the generation of immunologic memory [10].